Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pulse Biosciences ( (PLSE) ) has shared an announcement.
On March 12, 2026, Pulse Biosciences announced that the first patients were enrolled in a multicenter, first-in-human feasibility study evaluating its nPulse Vybrance Percutaneous Electrode System for treating T1N0M0 papillary thyroid microcarcinoma, a small, slow-growing form of thyroid cancer. Initial procedures were successfully completed at Sarasota Memorial Health Care System in Florida and The University of Texas MD Anderson Cancer Center in Texas, with a total of 30 patients planned across the two sites.
The study, conducted under an Investigational Device Exemption, will assess the safety and effectiveness of the Vybrance System in tumors under 1.5 cm, leveraging nsPFA energy to provide precise, nonthermal ablation while preserving critical surrounding structures. The device, already cleared by the U.S. Food and Drug Administration for soft tissue ablation, is partly funded by Pulse Biosciences for this thyroid cancer application, marking an operational step that could broaden its clinical footprint in minimally invasive oncology treatments.
The most recent analyst rating on (PLSE) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
PLSE scores below average primarily due to weak financial performance (minimal revenue, large losses, and elevated cash burn) and limited valuation support (negative P/E, no dividend). Offsetting these are improving longer-term technical positioning (above 50/100/200-day averages) and constructive earnings-call updates around IDE progress, clinical outcomes, and IP expansion, though near-term commercialization and funding needs remain key constraints.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences, Inc. is a bioelectric medicine company that develops its proprietary nPulse technology, which delivers nanosecond pulsed field ablation (nsPFA) energy to non-thermally clear cellular tissue while sparing adjacent noncellular structures. The company targets applications including atrial fibrillation and surgical soft tissue ablation, as well as non-cardiac indications through systems like its nPulse Vybrance Percutaneous Electrode System.
Average Trading Volume: 323,797
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.36B
For an in-depth examination of PLSE stock, go to TipRanks’ Overview page.